What happened with NTRA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Natera helps clinicians assess pregnancies, monitor cancer and evaluate organ health through molecular testing. Most revenue comes from three tests: Panorama for non-invasive prenatal screening, Horizon for genetic carrier screening, and Signatera, a personalized blood test that looks for cancer DNA remaining after treatment and monitors recurrence and treatment response.
Its U.S. direct sales force brings in most of the business, and Natera processes samples in its own laboratories. It bills insurers, patients and clinical or laboratory customers, with insurers providing most revenue. Laboratory partners also sell its tests. A smaller business licenses Constellation, which lets other laboratories perform testing locally and pay to use Natera’s cloud-based analysis software.
The business depends on clinicians ordering tests and insurers covering and paying for them; Natera performs testing before payment is assured. Many insurers do not cover Panorama’s microdeletion screening. Testing also relies on Illumina’s sequencing equipment and reagents, while several core tests depend on blood collection tubes supplied solely by Streck. Natera offers its clinical tests as laboratory-developed tests and must maintain laboratory certifications and state-specific permissions to continue testing in the relevant jurisdictions.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Natera’s results hinge on prenatal and cancer-testing volumes and insurer reimbursement, making Exact Sciences an important oncology rival to watch even though it is absent from this list.
BillionToOne, Inc. challenges Natera’s Panorama and Horizon prenatal and carrier screening business with UNITY tests that give physicians information about fetal risks. Its Northstar blood tests for treatment selection and response monitoring in late-stage solid tumors also overlap Natera’s oncology business; watch its prenatal sales expansion for pressure on Natera’s core screening franchise.
Guardant Health’s Reveal competes directly with Natera’s Signatera to detect cancer left after treatment and monitor recurrence. Guardant seeks Medicare and private-insurer payment for eligible U.S. Reveal patients, making coverage for this test a useful signal of the payment environment for cancer monitoring.
Myriad Genetics Inc competes with Natera in prenatal and carrier screening and is building a business that detects cancer remaining after treatment, or MRD, with Precise MRD. Watch how it uses its reach in community medicine to bring Precise MRD to clinicians, adding another challenge to Signatera.
CareDx, Inc. is Natera’s main organ-health rival, selling competing tests to monitor rejection in kidney, heart and lung transplant recipients. Watch adoption at transplant centers, where CareDx sells testing alongside digital tools and other services through the same customer channel.
Personalis, Inc. both competes with Signatera in cancer monitoring and sells Natera tumor analysis used to build its residual-disease tests. Natera accounted for 8% of Personalis’ revenue in 2025, down from 30% in 2024, a concrete measure of the supplier’s changing reliance on this partnership.
Natera cannot run Panorama, Horizon, Signatera or Prospera without the sequencing machines and reagents it buys from Illumina, which also competes in prenatal testing through Verinata. Natera’s tests are validated only on Illumina’s platform, so watch supply continuity and consumable costs under the agreement that expires in August 2033.
Tempus AI competes with Natera to sell cancer genomic tests to healthcare providers and life sciences companies. Its Diagnostics business is the relevant part to watch for this rivalry, rather than its separate sales of data and analytics tools.
Caris Life Sciences, Inc. competes with Natera in blood-based cancer monitoring and in selling genomic testing services to biopharma companies. Its clinical monitoring work and biopharma testing contracts are the relevant competitive signals, rather than its broader tissue-profiling business alone.
Labcorp’s specialty diagnostics business competes with Natera’s Panorama prenatal screening and Horizon carrier screening. Its Dx business receives payment from clients, patients and third-party payers; prenatal and carrier screening activity within Dx is more relevant to Natera than Labcorp’s separate drug-development laboratory business.
Quest Diagnostics competes with Natera in prenatal and carrier screening, and its acquired Haystack business adds cancer residual-disease testing to the overlap. Watch Haystack’s progress for the challenge to Signatera; Quest’s broader Advanced Diagnostics growth does not isolate that business.
Adaptive Biotechnologies Corporation and Natera both benefit from wider use of tests that detect cancer remaining after treatment, although clonoSEQ measures residual disease in blood cancers while Signatera uses circulating tumor DNA to monitor cancer. Adaptive’s clonoSEQ clinical-testing and biopharma drug-development revenue offers a distinct read on adoption of this testing approach.
Veracyte, Inc. identifies Natera as its primary rival in detecting residual disease in muscle-invasive bladder cancer. Watch clinical evidence and reimbursement progress for that MRD offering, rather than Veracyte’s current main revenue sources, Decipher Prostate and Afirma.
NeoGenomics, Inc. competes with Natera in cancer molecular testing for customers including community oncology and pathology practices, but withdrew its directly competing RaDaR residual-disease test after patent litigation. The withdrawal matters for Signatera’s competitive field, while the later 2025 court judgments invalidating two Natera patents are a separate legal development to watch.
Fulgent Genetics, Inc. competes with Natera’s Panorama and Horizon in non-invasive prenatal and genetic carrier screening. It sells laboratory testing and professional interpretation of results; watch its prenatal and carrier offerings rather than its separate therapeutic-development business when assessing the challenge to Natera.
CareDx, Inc. earningsCDNA
CareDx's report will show whether transplant centers are adopting its organ-rejection tests in the same customer channel Natera's Prospera serves.
Watch adoption of CareDx's tests at transplant centers, the customer channel it shares with Natera. Rising adoption would show CareDx building a stronger position there and could make it harder for Prospera to win testing business; weak adoption would offer less evidence that this rival is gaining ground. It is a read on competition, not proof that Natera has lost orders.
Illumina Inc earningsILMN
Illumina's report offers a read on the supply and cost conditions for sequencing machines and consumables that Natera relies on to run several tests.
Watch Illumina's disclosures about sequencing-platform demand, consumable supply and costs. Steady supply and limited cost pressure would suggest a more stable input for Natera's Panorama, Horizon, Signatera and Prospera tests. Disruption or rising consumable costs could constrain testing or raise the cost per test. Illumina's report is a supplier-side signal, not proof that Natera itself has experienced a change.
BillionToOne, Inc. earningsBLLN
BillionToOne's report will show whether its prenatal screening business is gaining traction against Natera's Panorama and Horizon.
Watch sales from BillionToOne's prenatal screening business. Faster growth would show its tests gaining ground in a market it shares with Natera, adding a competitive challenge, but would not prove that customers are leaving Natera. Weak growth would offer less evidence that this rival is expanding its reach.
Natera, Inc. earningsThis company
Natera's report will show how much of the growth from test volume and selling prices remains after the cost of running those tests.
Read product revenue and test volume alongside gross margin, the share of revenue left after direct testing costs. More tests and higher product revenue with a firmer margin would mean the added business is not being swallowed by costs. If volume rises but the margin narrows, or Natera reduces revenue estimates for tests delivered earlier, testing costs or insurer reimbursement and collection pressure may be eating into growth. Together, these figures show whether growth is improving what Natera keeps from its testing business.
Guardant Health, Inc. earningsGH
Guardant Health's report will show how much coverage and use its Reveal cancer-monitoring test is gaining, offering a payment-environment signal for Natera's competing Signatera.
Read Reveal's coverage progress alongside its use. Broader coverage with rising use would suggest that payment routes for cancer-monitoring tests may be opening up, while also making Guardant Health a more established direct rival. Limited coverage and weak use would offer less evidence of improving access to payment. Insurers' decisions about Reveal do not guarantee the same coverage for Signatera.
